Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 2

Probability of pharmacokinetic/pharmacodynamic target (fT > MIC ≥ 35%) attainment by CVVH flow rate in acute kidney impairment subjects with residual kidney function (250 mg q12h, 4-hour infusion).

MIC (mg/L)	CVVH flow rate (L/hr)
	0.5	1	2	3
1	0.984	0.981	0.973	0.963
2	0.603	0.573	0.514	0.455
4	0.021	0.017	0.012	0.008
8	0.000	0.000	0.000	0.000

Pharmacokinetic-pharmacodynamic target attainment probabilities for CVVH are based on a simulation of 5000 subjects using mean pharmacokinetic parameter estimates [14], with inflated between-subject variability (40% CV) and assuming a protein binding of 8.5% along with the presence of residual kidney function. Total drug CL represented a sum of 2 × CL_NR, renal CL, and CVVH CL. The renal component of the clearance allowed residual kidney function with a CrCL of 30 mL/min.